Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
about
Antiplatelet resistance in strokeCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceAntiplatelet therapy for carotid artery stentingPharmacogenomics and cardiovascular diseaseClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?The role of epoxyeicosatrienoic acids in the cardiovascular systemUp-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 CellsVariable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Pharmacogenomics and personalized medicine: lost in translation?Applied pharmacogenomics in cardiovascular medicineInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Antiplatelet drug interactions with proton pump inhibitorsImpact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Implementing genotype-guided antithrombotic therapy.Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyRealities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionInfluences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypesEffects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery diseaseCurrent concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Emerging clinical applications in cardiovascular pharmacogenomics.Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisInsurance coverage policies for personalized medicine.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
P2860
Q22305927-06BD38D2-B0A3-45C6-9944-757286EABFEDQ26771106-51A25BEA-0CDC-4434-8A60-B9A390B0812DQ26775125-8BEC8E59-1B71-4329-878B-A7A101E84001Q26801867-01E96B9B-4D8E-4282-B127-CF02F3A4E71BQ26822796-63EA3966-C681-4DF7-8D01-B2A948005E36Q26823542-11AE1B18-04BE-4013-B260-A26D8BC81F29Q26824850-F7EF2FFF-FDEC-40F3-A7F0-9E988AA12FDCQ26852304-7D8311AA-65B5-4E66-8398-BC2FDFD32B57Q26997380-0E399EDF-9E71-43BB-92C0-6C264AD0FFE3Q27011524-F2186CE8-1BF2-41CA-807E-042689A1B409Q27022443-02668888-C7F4-4979-B98C-B3F770DDF0ECQ28256560-A356E1C4-9031-4CC9-A0ED-DCF88E4468E0Q28553219-8F4F9980-0AB3-4BD0-8815-3482CFA8B2F4Q30498026-36A87E45-7955-4031-A1FD-1322B78DD2B2Q33554381-38408B9C-BC10-40B4-97B2-54919B012304Q33584173-3BB2993E-37E6-4B00-8477-8A851C8D0AE7Q33622182-6AAB807F-15D7-48C8-BC6C-8EF2D0EEAA8CQ33637840-1EF9122D-EBF5-407C-AEAB-F022A74FEA7DQ33704998-2750B5A0-43B1-4B94-A80E-E820A3124482Q33762268-5084CD71-3000-49C5-B0DA-4B3CE6BB1068Q33846255-F7525F69-9D9D-468B-BBC9-CDEE96CF88FEQ33933475-30D06E5E-1E3E-4C06-B849-70F6FF46A8C9Q33948811-8A58F4E3-4D99-4FA5-BC2B-91C144810B30Q33982372-57CD9F51-65EC-4065-8D26-9F1FF079EB7AQ33990428-5BFD2E38-6E4C-4D94-A0B4-AA850D17376CQ33997642-3481C2DE-86CC-4B52-A00E-B58ECC740DF0Q34019082-3BDBCF11-9A17-4436-902B-9EA8CAB34C73Q34131354-F77C7914-023E-4114-91CD-8CCC1D1EF672Q34161006-D7216999-1D65-44D3-BED7-386F41302A6FQ34166239-7AE4DB0E-B523-4312-BA3B-E7B126A8F898Q34174915-B22C8471-E905-49DE-AE27-6DDDC14855FEQ34352152-E8AC2DEC-55A4-4E24-A49D-F145894A34BBQ34382431-E0B0CE0D-BCD0-478A-BAE4-28EF7F1F1D15Q34400491-7E5B44DC-23E0-445E-AD6A-9301F794923BQ34419173-94F5F8E9-4310-4FFE-9CFF-991701F70DFBQ34552473-518D3106-7320-44FE-B7C5-CB375A1CB031Q34564576-A37E59CC-352A-47CC-92BA-430DD2735EACQ34608654-E86B4834-2F85-421E-9FE6-A6652339702DQ34624862-69E943B2-64C4-4467-BF50-F247188D0C68Q34649009-0148703D-C305-485A-8BFC-BDEBE913B1EF
P2860
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@ast
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@en
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@nl
type
label
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@ast
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@en
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@nl
prefLabel
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@ast
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@en
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@nl
P2093
P50
P1433
P1476
Cytochrome P450 2C19 polymorph ...... al infarction: a cohort study.
@en
P2093
Delphine Brugier
Gilbert Bensimon
Jean-Baptiste Esteve
Jean-Philippe Collet
Laurent Payot
P304
P356
10.1016/S0140-6736(08)61845-0
P407
P50
P577
2008-12-26T00:00:00Z